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When I had completed medical school and graduate school, the scientific
world did not even have the correct figure for the number of human
chromosomes. Greggl had recently described the teratogenicity of rubella
virus infection during pregnancy The teratogenic risk of the folic acid
antagonists was established2"and there were experimental studies indicating
that nutritional deficiencies could produce birth defects in anirnal~.~
What have we learned and accomplished in the past 50 years? Thousands
of previously unknow7n genetic diseases have been described and many of
their genes have been identified since the 1 9 5 0 ~The
. ~ ~fields of prenatal
intrauterine diagnoses, intervention and treatment have been created.
Metabolic and biochemical screening have become standard care for pregnant
women and newborns. Over 50 teratogenic environmental drugs, chemicals
and physical agents have been described7-lousing modern epidemiological
tools and the talents of clinical dysmorpho1ogists."-l7 The basic science and
clinical rules for evaluating teratogenic risks have been established (Table l ) . I s
The development of the rubella vaccine and the recognition of the importance
of adequate folic acid intake in women of reproductive age are forerunners for
the prevention of birth defects from teratogenic infectious agents and
nutritional components that are important for normal development. The
completion of the first stage of the Human Genome Project in the year 2000
offers the geneticist and teratologist immense opportunities to evaluate the
concepts of polygenic and multifactorial e t i o l o g i e ~ ' ~of
, ~ ~congenital
malformations.
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Table 1 Evaluation of the allegation that a particular environmental agent causes
congenital malformations or is responsible for malformations in an individual patient

Epidemiological studies
Controlled epidemiological stucAies consisi:ently demonstrate a
increased incidence of a par tic^~ l a spectri
r
Jm of embryonic and
fetal effects in exposed human populatio~
ns
Secular trend data
Secular trends demoristrate a positive relzttionship between the
changing r?xposuresI:O a commson enviror mental agent in human
populatiorIS and the incidence Iof a particlular embryonic and/or fetal
eff ect
An imal devellopmental toxicity st1udies
1 mimics t ble human
An animal model carI be develc
~.cllnlcally
. compara~le
-,
developmetntal effecl,c ar
exposures.. Since
.
mimicry may not occur in all animal species, animal models are morn
likely t o be developed once there is good evidence for the
embryotoxic effects reported in the human. Developmental to
studies in animals are indicative of a potential hazard in gene1
rather than the potential for a specific adverse effect on the ft,,
,
when therle are no h~uman dataI on which t o base the animal
experiments
~

8

.

0 -

8

~

~

-

voseresponse relartonsnlp (pnarmacorlnerlcs ana roxlcorlnerlcc
5).
.
Developmental toxicity in the human increases with dose (exp
and the de!velopmen.tal toxicity in animal occur at a dose that
pharmacoktinetically I(quantitatively) equi\lalent t o tl7e human
exposure
Bia

.

~usibility
The mechalnisms of develop me^i t a l toxicity are understood and the
effects are biologically plausiblf2:. , - - Mechanisms of actlon (MUA)
Receptor studies
Nature (~fthe mallformations
Teratololgy principles

-.

Modified from several rererences.r.o.L"26.3"8.41

EMOTIONAL IMPACT OF CONGENITAL MALFORMATIONS
Reproductive problems encompass a multiplicity of diseases including
sterility, infertility, abortion (miscarriage), stillbirth, congenital malformations
(due to environmental or hereditary etiologies), fetal growth retardation and
prernat~rity.7-'"'~These clinical problems occur commonly in the general
population and, therefore, environmental causes are not always easy to
corroborate (Table 2). Severe congenital malformations occur in 3% of births.
According to the Centers for Disease Control, severe congenital malformations
(including those birth defects that cause death, hospitalization, and mental
retardation) necessitate significant or repeated surgical procedures, are
disfiguring, or interfere with physical performance. That means that each year
in the US, 120,000 newborns are born with severe birth defects. Genetic
diseases occur in about 11% of births. Spontaneous mutations account for less
than 2-3'10 of genetic disease. Therefore, mutations induced from
preconception exposures of environmental mutagens are difficult end-points
to document (Table 2). It may surprise the reader to know that birth defects
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account for 440,000 children's deaths each year in the low- and middle-income
nations from congenital malformations. That represents 3.7% of the deaths in
children. In the high-income countries, congenital malformations are the
second highest cause of death in children, accounting for 20% of the deaths.

DISEASES OF AFFLICTION
Along with cancer, psychiatric illness, and hereditary diseases, reproductive
Problems have been viewed throughout history as diseases of affliction.
Inherent in the reactions of most cultures is that these diseases have been
viewed as punishments for
Regardless of the irrationality of this
viewpoint, these feelings do exist. Ancient Babylonian writings recount tales of
mothers being put to death because they delivered malformed infants. One
George Spencer was slain by the Puritans in New Haven in the 17th century,

5

having been convicted of fathering a cyclopean pig, since the P~lritanswere unable
to differentiate between George Spencer's cataract and the malformed pigs cloudy
In modem times, some individuals with reproductive problems reverse
the lustorical perspective, and blame others for the occurrence of their congenital
malformations, infertility, abortions and hereditary diseases. They place the
responsibility of their illness on environmental agents dispensed by their
healthcare provider or utilized by their employer."-24
Reproductive problems alarm the public, the press and some scientists to a
greater degree than most other diseases. In fact, severely malformed children
are disquieting to healthcare providers, especially if they are not experienced
in dealing with these problems. No physician will be comfortable informing a
family that their child was born without arms and legs. The objective
evaluation of environmental causes of reproductive diseases is clouded by the
emotional climate that surrounds these diseases, resulting in the expression of
partisan positions that either diminish or magnify the environmental risks.
These non-objective opinions can be expressed by scientists, the laity or the
press.aZ4It is the responsibility of every physician to be aware of the
emotionally charged situation when a family has a child with a birth defect.
The inadvertent comment by the physician, nurse, resident or student in
attendance at the time of the child's delivery can have grave consequences for
the physician and the family. Comments such as, 'Oh, you had an X-ray during
your pregnancy', or 'You did not tell me that you were prescribed tetracycline
while you were pregnant', can direct the patient's family to an attorney rather
than to a teratology or genetic counselor.

BASIC PRINCIPLES OF TERATOLOGY
Labeling an environmental exposure as teratogenic is inappropriate unless one
characterizes the exposure with regard to the dose, route of exposure and the
stage of pregnancy when the exposure occurred. Labeling an agent as
teratogenic only indicates that it may have the potential for producing
congenital malformations. A 50-mg dose of thalidomide administered on the
26th day post-conception has a significant risk of malforming the embryo. That
same dose taken during the 10th week of gestation will not result in congenital
malformation^.^ One milligram of thalidomide taken at any time during
pregnancy will have no effect on the developing embryo. We know that Xirradiation can be t e r a t o g e n i ~However,
. ~ ~ ~ ~ if the dose is too low or the X-ray
does not directly expose the embryo, there is no increased risk of congenital
SO a list of teratogens only indicates teratogenic
malformations (Fig. l).7,8,26
potential. Evaluation of the dose and time of exposure could indicate that there
is no teratogenic risk or that the risk is significant.
When evaluating studies dealing with the reproductive effects of any
environmental agent, important principles should guide the analysis of human
and animal reproductive studies. Paramount to this evaluation is the
application of the basic science principles of teratology and developmental
biol~gy.~
These
, ~ , ~principles
~
are as follows:
I. Exposure to teratogensfollows a toxicological dose-response curve. There is a

threshold below which no temtogenic efiect will be observed; as the dose ofthe

teratogen is increased, both the severity andfrequency of reproductive effects will
increase (Fig. 1; Table 3).
2. Tke embryonic stage of exposure is critical in determining what deleterious eflects
zoill be produced and whether any of tlzese effects can be produced hj a known
teratogen. Some teratogenic Effects have a broad, and others a very narrow, period
of sensitivity. The most sensitive stage for tlze induction of mental retardation
from ioiziziizg radiation i s f r o n ~the 8th to 15tl1 week of pregnancy, a lengthy
period. Thalidomide's period of sensitivity is about 2 weeks (Table 4).25
3. Even tlze most potent teratogenic agent cannot produce m e l y rrmlformatiolz.
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Fig. 1. Dose-response relationship of reproductive toxins comparing preconception and
post-conception risks. Reprouced with permissionof Wiley-Liss Inc O 1999 from Brentz6
Table 3 Stochastic and threshold dose-response relationships of diseases produced by
environmental agents
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Table 4 Developmental stage sensitivity t o thalidomide-induced limb reduction defects
in the human
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4. Most teratogens have a confined grotip of congenital malformations that result

I

after exposure during a critical period of embryonic development. This confined
grot~pof malformations is referred to as the syndrome that describes the agent's
teratogenic effects.

I

5. While a grotip of malformations may suggest the possibility of certain teratogens,
they cannot definitively confirm the causal agent because some teratogenic
syndromes mimic genetic syndromes. O n the other hand, the presence of certain
malformations can eliminate the possibility that a particular teratogenic agent
was responsible because those malformations have not been demonstrated to be
part of the syndrome or because the prodliction of that malformation is not
biologically platisible for that particular alleged tmatogen.

The etiology of congenital malformations can be divided into three categories
- unknown, genetic, and environmental (Table 5). The etiology of a majority of
human malformations is unknown. A significant proportion of congenital
malformations of unknown etiology is likely to have an important genetic
component. In fact, newly published findings are describing genetic causes for
malformations or syndromes whose etiology were previously listed as
unknown. Malformations with an increased recurrent risk, such as cleft lip and
palate, anencephaly, spina bifida, certain congenital heart diseases (pyloric
stenosis, hypospadias, inguinal hernia, talipes equinovarus, and congenital
dislocation of the hip) fit in the category of multifactorial disease as well as in
the category of polygenic inherited disea~e.'~,'~
The multifactorial/threshold
hypothesis postulates the modulation of a continuum of genetic characteristics
by intrinsic and extrinsic (environmental) factors.
Spontaneous errors of development may account for some of the
malformations that occur without apparent abnormalities of the genome or

I

I
I

Table 5 Etiology of human congenital malformations obsewed during the first year of life*
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environmental influence. Spontaneous errors of development may indicate
that we may never achieve our goal of eliminating all birth defects because a
significant percentage of birth defects are due to the statistical probability of
errors in the developmental process, similar to the concept of spontaneous
mutation. It is estimated that 3040% of all conceptions are lost before term,
many within the first 3 weeks of development. The World Health Organization
estimated that 15% of all clinically recognizable pregnancies end in a
spontaneous abortion, 50-60% of which are due to chromosomal
abn~rrnalities.~'-~~
Finally, 3 4 % of offspring are malformed, which represents
the background risk for human maldevelopment (Table 2).

FACTORS AFFECTING SUSCEPTIBILITY TO DEVELOPMENTAL
TOXICANTS
A basic tenet of environmentally produced malformations is that teratogens or
a teratogenic milieu have certain characteristics in common and follow certain
basic principles. These principles determine the quantitative and qualitative
aspects of environmentally produced malformations.
Embryonic stage

The types and risk of malformations caused by teratogenic agents usually
results in a spectrum of malformations that varies depending on the stage of

exposure and the dose. The developmental period at which an exposure occurs
will determine which structures are most susceptible to the deleterious effects
of the drug or chemical and to what extent the embryo can repair the damage.
This period of sensitivity may be narrow or broad, depending on the
environmental agent and the malformation in question. The period of
susceptibility to thalidomide-induced limb defects is very narrow (Table 4),25
while susceptibilityperiod for radiation-induced microcephaly is very broad.26
Dose or magnitude of the exposure

The quantitative correlation of the magnitude of the embryopathic effects to
the dose of a drug, chemical or other agent is referred to as the dose-response
relationship. This is extremely important when comparing effects among
different species because the use of mg/kg doses is ,at most, a rough
approximation. Dose equivalence among species for drugs and chemicals can
only be accomplished by performing pharmacokinetic studies, metabolic
studies and dose-response investigations in the human and the species being
studied, while ionizing radiation exposures in rads or Sieverts (Sv) are
comparable in most mammalian species.26
Threshold dose

The threshold dose (no-adverse-effect-level, NOAEL) is the dosage below
which the incidence of death, malformation, growth retardation, or functional
deficit is not statistically greater than that of controls (Fig. 1; Table 3). The
threshold level of exposure is usually from less than one to two orders of
magnitude below the teratogenic or embryopathic dose for drugs and
chemicals that kill or malform half the embryos. An exogenous teratogenic
agent, therefore, has a no-effect dose as compared to mutagens or carcinogens
that have a stochastic dose response curve (Fig. 1; Table 3). Stochastic
phenomena, namely mutation and oncogenesis, are hypothesized not to have
a threshold. Therefore, there is no exposure that does not have a theoretical
risk. The severity and incidence of malformations produced by every
exogenous teratogenic agent that has been appropriately studied have
exhibited threshold phenomena during organogenesis.
Pharmacokinetics and metabolism of the drug or chemical

The physiological alterations in pregnancy and the bioconversion of
compounds can significantly influence the teratogenic effects of drugs and
chemicals by affecting absorption, body distribution, active form(s) and
excretion of the compound.

Physiological alterations in the mother during pregnancy afect the plzarmacokinetics
of drugs:
1. Decreased gastrointestinal motility and increased intestinal transit time

resulting in delayed absorption of drugs absorbed in the small intestine
due to increased stomach retention and enhanced absorption of slowly
absorbed drugs.

2. Decreased plasma albumin concentration which alters the kinetics of
compound normally bound to albumin.

3. Increased plasma and extracellular fluid volumes that affect concentrationdependent transfer of compounds.
4. Renal elimination, which is generally increased but is influenced by body
position during late pregnancy.
5. Inhibition of metabolic inactivation in the maternal liver.
6. Variations in uterine blood flow, although little is known about how this
affects transfer across the placenta.

Thefetus also undergoes physiological alterations that aflect the phnrmacokinefics of drugs:
1. The amount and distribution of fat varies with development and affects
the distribution of lipid-soluble drugs and chemicals.
2. The fetal circulation contains a higher concentration of unbound drug largely
because the plasma fetal protein concentrations are lower than in the adult.

3. The functional development of pharmacological receptors is likely to
proceed at different rates in the various tissues.
4. Drugs excreted by the fetal kidneys may be recycled via amniotic fluid
swallowing by the fetus.
The role the placenta plays in drug pharmacokinetics has been reviewed by
Juchau and Rettie35and involves: (i) transport; (ii) the presence of receptors sites
for a number of endogenous and xenobiotic compo~mds (P-adrenergic,
glucocorticoid,epidermal growth factor, IgG-Fc, insulin, low-density lipoproteins,
opiates, somatomedin, testosterone, transcobalamin II, transferrin, folate,
retinoid); and (iii) the bioconversion of xenobiotics. Bioconversion of xenobiotics
has been shown to be important in the teratogenic activity of several xenobiotics.
There is strong evidence that reactive metabolites of cyclophosphamide, 2acety:aminofluorene, and nitroheterocycles (niridazole) are the proximal
teratogens. There is also experimental evidence that suggests that other chemicals
undergo conversion to intermediates that have deleterious effects on embryonic
development including phenytoin, procarbazine, rifampicin, diethylstilbestrol,
some benzhydrylpiperazine ,antihistamines, adriamycin, testosterone,
b e n ~ o ( a ) ~ ~ r emethoxyethanol,
ne,
caffeine, and paraquat.
The major site of bioconversion of chemicals in vivo is likely to be the
maternal liver. Placental cytochrome P450-dependent monooxygenation of
xenobiotics will occur at low rates unless induced by such compounds as those
found in tobacco smoke. However, the rodent embryo and yolk sac have been
shown to possess functional cytochrome P450 oxidative isozyrnes capable of
converting pro-teratogens to active metabolites during early organogenesis. In
addition, cytochrome P450-independent bioactivation has been suggested: for
example, there is strong evidence that the rat embryo can reductively convert
niridazole to an embryotoxic metabolite.
As defined by Juchau and Rettie,35 there are several experimental criteria
that would suggest that a suspected metabolite is responsible for the in vivo

teratogenic effects of a chemical or drug: (i) the chemical must be convertible
to the intermediate; (ii) the intermediate must be found in or have access to the
tissue(s) affected; (iii) the embryotoxic effect should increase with the
concentration of the metabolite; (iv) inhibiting the conversion should reduce
the embryotoxic effect of the agent; (v) promoting the conversion should
increase the embryotoxicity of the agent; (vi) inhibiting or promoting the
conversion should not alter the target tissues; and (vii) inhibition of
biochemical inactivation should increase the embryotoxicity of the agent. It is
readily apparent why there may exist marked qualitative and quantitative
differences in the species' response to a teratogenic agent.
Placental transport

The placenta controls the exchange between the embryo and the maternal
organism. The placenta varies in structure and function among species and for
each stage of gestation. Thus, differences in placental function and structure
may affect our ability to apply teratogenic data developed in one species
directly to other species, including the human. Yet, as pharmacokinetic
techniques and the actual measurement of metabolic products in the embryo
become more sophisticated, the appropriateness of utilizing animal data to
project human effects may impr0ve.3~
While it has been alleged that the placental barrier was protective and,
therefore, harmful substances did not reach the embryo, it is now clear that
there is no 'placental barrier,' per se. Yet the package inserts on many drugs
state that: 'this drug crosses the placental barrier'.2hThe uninitiated may infer
From this statement that this characteristic of a drug is both unusual and
hazardous. The fact is that most drugs and chemicals cross the placenta. It will
be a rare chemical that will cross the placental barrier in one species and be
unable to reach the fetus in another. No such chemical exists except for selected
proteins whose actions are species-specific.
Genetic differences

The genetic constitution of an organism is an important factor in the
susceptibility of a species to a drug or chemical. More than 30 disorders of
increased sensitivity to drug toxicity or effects in the human are due to an
Inherited trait.

ENVIRONMENTAL AGENT EXPOSURE DURING PREGNANCY
RESULTING IN REPRODUCTIVE TOXICITY7-9
Table 6 lists environmental agents that have resulted in reproductive toxicity
and or congenital malformations in human populations. The list cannot be
used in isolation because so many other parameters must be considered in
analyzing the risks in individual patients. Many of these agents represent a
very small risk while others may represent substantial risk. The risks will vary
with the magnitude, timing and length of exposure. More information can be
obtained from more extensive reviews or summary articles. Table 7 includes
agents that have had concerns raised about their reproductive risks but, after

Table 6 Proven human teratogens or embryotoxins: drugs, chemicals, milieu and
physical agents that have resulted in human congenital malformations
REPRODUCTIVETOXIN AND ALLEGED EFFECTS
Aminopterin, m~ethotrexz
te - growtlh retardati on, microc
memingomyelocele merltal retardintion, hydr
, and cleft
pa'late
Androaens - mdscullrllrdilurl ui Lrle developiny leLus Ldll urrur l r u r r l d~luruyt
antd high doses of some male-derived progestins
Angic~tensincot~vertingenzyme (ACE) inhibitors - fetal hypotension syndrom
2n1cl and 3rd trimester resulting in fetal kidney hypoperfusion, at
,-a,
. l luria, oligohydramnios, pulmonary hypoplasia and cranial bonc
No teratogenic effect in the firs1: trimester although
h ~~oplasia.
l
recent publicationg contests this conclusion
Angic
eceptor blocking agents - the effects o f this group of drugs is very
iilar t o the ACE inhibitors
Antit1uberculour;therapy -- INH, PAS has an inc~
-eased risk for some CNS
a bnormalitie!
~
>
Caffeine - modc?rate caffe ine exposure is not associated r~ i t birth
h
defects; hi
-. ...- .
. .....- ..
. I-.
*
t!xposures are associated with an increase0 risk of aborr~onDur rrie
Cjata are inconsistent
Chorionic villc>us sampling (CVS) - visscular disr
1
reduction defects
.. . .
Cobalt In hematemic multivitamins - fetal goiter
Cocaine - vascular disruptive type malformations in very low incidence, pregrlancy
loss. Inconsistent reports of decrease in cognitive fundtion
... . . ~
Corticosteroids- high exposures administered systemically have a low risk tor clett
palate in some studies, but the epidemiological studies are not consistent
Coumarin derivatives - early exposure during pregnancy can result in nasal
hypoplasia, stippling of secondary epiphysis, intrauterine growth
retardation. CNS malformations can occur in late pregnancy exposure
due t o bleeding
Cyclophosphamide and other chemotherapeutic agents and immunosuppressive
agents like cyclosporine or leflunomide - many chemotherapeuti
agents used t o treat cancer have a theoretical risk for producing
nalformations in the fetus when administered t o pregnant women.
!specially since most of these drugs are teratogenic in animals, but
he clinical data are not consistent. Many of these drugs have not
)een shown t o be teratogenic, but the numbers of cases in the
>tudies are small. Caution is the byword
Diethylstilbestrol - administration during pregnancy produces genital
abnormalities, adenosis, clear cell adenocarcinoma of vagina in
adolescents. The latter has a risk of 1:1000 t o 1:10,000, but the other
nffects, such as adenosis can be quite high
Ethyl
Fetal alcohol syndrome consists of microcephaly, mental
ardation, growth retardation, typical facial dysmorphogenesis,
iormal ears, small palpebral fissures. It is the most common
,..ilironmental cause of a decrease in intellectual performance
Ionizing radiation - t h e threshold for major birth defects is greater than 20 ri
(0.2 Gy) at the most sensitive stage of embryogenesis (18-35 day
post-conception). Radiation can increased the risk for some fetal
effects such as micocephaly or growth retardation at mid-gestati-. .,
but the threshold for these effects is higher
Insulin shock therapy - this therapeutic modality when administered t o pregnant
women resulted in microcephaly, mental retardation. This therapy is no
longer used
Lithium therapy - continuous exposure during pregnancy for the treatment of
manic-depressive illness has an increased risk for Ebstein's anomaly
and other malformations, but the risks appear t o be very low
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Table 6 (continued) Proven human teratogens or embryotoxins: drugs, chemicals,
milieu and physical agents that have resulted in human congenital malformations
Minoxidil - t h e effect of the growth promotion of fetal hair was discovered for
"iis drug because administration during preanancv resulted in
irsutism in newborns
mothers
Methimazole -- aplasia cutis has been reported t o be in(
a1dministered this drucj during PI'egnancy*
. .
..
... .
Methylene blue intra-amniotic instillation - tetal intestinal atresla, hemolytlc
Are is no Icmger
nemia and jaundice in neonata I period. TIhis proced~
dentify on1e twin
tilized t o i~
Misc
a low inciclence of v: 3scular disruptive phcmomena, riuch as limb
, ..
.. , .
.~-,.~
rc?auction aefects and MODIUS syndrome have Deen repomea In
Pregnancies in which this drug was used t o induce an abortion.
A utism has also been associated with in utero exposures5
Peniicillamine (:D-penicillamine) -this drug results in the physical effects refelrred t o
a:s lathyrism, the results of poisoning by the seeds of the genus
Liathyrus. I t causes collagen disruption, cutis laxa, and hyperflex ibility
0f joints. The condition appears t o be rever2ible and the risk is Ilow
Pro5jestin therapy - very high doses of androgen hormonecierivedprogestins ci3n
-,
roduce masculinization. Many drugs with progestational activity d'u .I-*I U L
ave masculinizing potential. None of the commonly used progestational
rugs have the potential for producing non-genital malformations
:il-this drug and other antithyroid medications administered
pro^
Uuring pregnancy can result in an infant born with a goiter
Radiioactive isc,topes - tissue- and organ-specific damage is dependent on t t
T itdioisotope element and distribution, i e . high doses of ')'I
a13ministered t o a pregnant woman can cause fetal thyroid
h!ypoplasia after the 8th week of developrront
Retinoids (Acuitane) - systemic retinoic acid, isotretinoin, Etretinate can cause
in[creasedrisk of central nervous system, carclio-aortic, e!ar and clefting
dlefects. Microtia, anotia, thymic aplasia and other branchial arch, aortic
.
a1*ch abnormalities and certain congenital heart maltormtinnc
Retinoids, topiical -topical administration is very unlikely t o have teratogeni
P'otential because one cannot attain a teratogenic serum level 1
t c)pica1 exposure t o retinoids
Streptomycin -streptomycin and a group o f ototoxic drugs can affect the ei,,.,
,
erve and interfere with hearing; it is a re1atively low
henomenon. Even children are less sensitive t o the (
f these drugs when compared t o adults
Sulfa drug and vitamin K - these drugs can produce hemolysls In .cnma
subpopulations of fetrJses
one and t e:eth stainirig, No othler malforniations
Tetracycline -this drug produces b~
are at increased risk
Thalidomide -this drug results in an 11 tc, r a x u II ,cruel Icr uf deafness, of I V L I ~ , PI =-axial
limb reduction defects, phocomelia, ventricular septa1 defects and GiI
atresias. The susceptible period is from the 22nd t o the 36th day polstconception. Autism has also been associated with in utero exposure55
Trimethorpin -this drug was frequently used t o treat urinary tract infections , ,,
as been linked t o an increased incidence of neural tube defect:s. The
~
sk is not high, but it is biologically plausible because of the d rug's
ffect on lowering folic acid levels. This has resulted in neurolo!jical
Imptoms in adults takincl
- this drug
Vita min A - t he same m i~ l f o r m a t ii os ~that ha^re been re1~ o r t e dwit1h the retinoids
h<ave been reported w ith very hitg h doses of vitamin 14 (retinol).
DOsages t o produce birth defect!j would haIve t o be ir1 excess of
215,000-50,000 units pc?rday
. -. .
Vitamin D* - 1,arge doses given in v,itamin D F)rophylaxis are possit~ l involve(
y
J in
t k\e etiologyI of supravalvular aor'tic stenosi:s, elfin facc2s. and mental
reTardation
~

#

-

-

-

1
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Table 6 (continued) Proven human teratogens or embryotoxins: drugs, chemicals,
milieu and physical agents that have resulted in human congenital malformations
I

Warfarin (Coumarin) - early exposure during pregnancy can result in nasal
hypoplasia, stippling of secondary epiphysis, intrauterine growth
retardation. CNS malformations can occur in late pregnancv exposure
due t o bleedir19
ANTIC

.

---A

-L

NTS

--

:--"Am--

!

feta I hydantoin syndrome, consisting of facia l dysmorpliology, cleft
pala~te,VSD, growth and mental retardation
Trimethadione a1i d paramethadione -treatment of convulsive disorcders increa~ses
*L_
.
.
.-*--A
-.
r n e risk of characteristic facial dysmorphologv. nlenral reraruarlori, Vshalled eye b rDWS,
~
low-s~
et ears with anterior iy folded t-~elix,higharchled palate. irregular 1teeth, CNS anomaliesi, severe dcwelopmer~ t a l
delalY
.
.
Valpro~cacla - rrearmenr OT convulsive disorders increases m e rlsK OT splna ~ l ~ i d a ,
farigl dysrnorphology and autism.55A threshold (NOAEL) has been
jested for exposures below 1000 mgtday and a serum level below
g%
Carbamazeplne -treatment of convulsive disorders increases m e rlsl< Taclal
dysmorphology
Primidone, phen~
vulsants obarbital, Lamotrigirle and 0th'
anti convulsants all have real or hyp
risks for a group of
.
.
~. -.
.
. ..
marFormations and reduct~onIn cognltlve tunctlon. I ne actual rlsKs
are difficult t o determine, but most authorities are of the opinion
that: some type of regimen must be utilized t o prevent or decrease
con!~ulsiveepisodes during pregnancy. Anticonvulsant polytherapy
nnrr,
1 L 1 'eases the risk of developmental, C
----+,UCLL>
..._-A_,

-A:

I,

HEMICALS
CarborI monoxide poisoning - CNS diamage has been repcr t e d with very high

-r....^r

l...4

....---.-

+-

I^ ^ I^...*

Je l u v v

Lead -very high exposures can cause pregnant)1 loss; intri
ratogenes
the serum
not established at very low exposulres below
pregnant mothers
Gasoline addiction embryopathy - facial dysmorphology, mental retardation
MethyI mercury .- Minamata disease consists of cerebral palsy, microcephaly,
mer~ t aretardation,
l
blindness, cerebellum hypoplasia. Other endemics
havc occurred from adulteration of wheat with mercury containing
chernicals that are used t o prevent grain spoilage. Present
environmental levels of mercury are unlikely t o represent a
teratogenic risk, but reducing or limiting the consumption of
carr~ivorousfish has been suggested in order not t o exceed the EPA's
*
lvlrti (maximum permissible exposure). which is far below the toxic
eff ects of mercury
Polychlorinated Ibiphenyls - poisoning has occu~
,red from i3dulteratic)n of food
procducts (Cola-colored babies, CNS effects, pigmentatioIn of gums,
, ,
., . .
. .
nalls, teeth and groin; hypoplastic aeTormea nalls; lnrraurer~ne
ireshold
growth retardation; abnormal skull calcification). The tl
exposure has not been determined, but it is unlikely t o be
teratogenic at the present environmental exposures
Toluene and gasoline addiction - facial dysmorphology, mental retarnattnn
m,.,

EMBRYONIC PrND FETAL INFECTIOF4s
Cytomegalovirus infection - retinopathy, CNS c ialcification, microcephaly, men1
retardation
Rubella - deafness, congenital heart dislease, micro1cephaly, caitaracts, mental retardation

Table 6 (continued) Proven human teratogens or embryotoxins: drugs, chemicals,
milieu and physical agents that have resulted in human congenital malformations
Herpes simalex -fetal infection, liver disease. death
~
iciency virus - 1perinatal Ii I V infectic
Hunnan i m m unodef
Panrovirus infection, B I !9 - stillbirt h, hydrops
,
.
SYP hilis - mac:ulopapular rasn, nepatosplenomegary, aeTormea n:
steochondritis at joints of extremities, congenital neurosyphiliIS.
bnormal epiphyses, chorioretinitis
ental retar.dation
TOXI
;- hydroct?phaly, microphthalmia, chorio~
,.
L._.I.A:._
Varice~laLosrer - stun and muscle defects, intrauterine growrn reraraarlon. limb
sduction defects, CNS damage (very low increase ris;k)
Venezuelan ecquine ence!phalitis - hydranencephaly, microphthalrnia, centraI
nervous system destructive lesions, luxation of the hiP.
*- - - A
Rubeo~a(wlla-rype measles) -the measles virus can infect the olacenra
arid '"'SIsvere infection can cause pregrIancy loss, which ;i uncommon
~
aternal d emise
Malaria - prec
i by miscar.riage or s t illbirth. M8

.

.

.1

MA1 t K N H L V l S t H S t S I H I t:
'
Codticosteroid secreting endocrinopathy - mothers wit1h Cushing's alsease c,an
have infants with hyperadrenocortism, bu.t anatomic:al malfornnations
do not appear t o be increased
7cy - can result in embryonic goiter and mental retardation
lodi
lntriauterine problems of constraint and vascular disruption -these types oif
defects are more common in multiple-birth pregnancies, pregnancies
VIlith anatomical defects of the uterus, placental emboli, amnialtic
ands; birth defects such as club feet, limb reductiorI defects, aplasia
utis, cranial asymmetry, external ear malformations,, mid-line (:losure
efects, cleft palate and muscle aplasia, limb reducti'on defects, cleft
p, omphalocele, encephalocele)
Mat
,ogen endocrinopathy (adrenal tumors) - masculinization
~essionand the use of antidepressants - at the present time, there is
Mat
controversy as t o whether the SSRl exposures during pregnancy
?present a risk for congenital malformations. The data are
iconsistent and more studies and well-performed animal stud ies are
e c e s ~ a r yThere
. ~ ~ ~is~data indicating the presence of fetal grow t h
~tardationand postnatal hyperactivity that is transient
Maternal alabetes - caudal and femoral hypoplasia, transposition of great \
nd other malformations
Mat:ernal folic acid in reduced amounts - an increased incidence I3f neural t ube
d efects (NTDs) and possibly other mid-line malformations
.
.
..
Maternal pnenylketonuria -abortion, microcephaly, ana mental retaraatlon. very
high risk in untreated patients
Maternal starvation - IUGR, abortion, NTDs
Tobacco smoking -abortion, IUGR, and stillbirth. Question of decrease in
3gnitive function a possibly antj increase in some birth defect!
lthough this is contrc3versial
Zinc def icienclI - neural tube defeC t S *
9.

.

.

*Controvers~al.

careful and complete evaluation, the agents were found not to represent an
increased reproductive risk.-'
References for the environmental agents can be found in review articles and
texts dealing with t e r a t o g e n e s i ~ . ~ , ~ , ~ ~ , ~ ~ , ~ ~ , ~ ~ ~ ~

Table 7

Agents erroneously alleged t o have caused human malformations

Bendr
?geat o cause numerous types or o ~ r t haerects lncluaing limo
tions and many other
reduction def~
ects, heart
ma'lformations
Diagnostic ultra!sonograph'!
..
No significant nypertnermla, tnererore no reproductive effects.
NelNer ultraso~undequip ment and lengthy procedures could raise the
intr,auterinec
t .mperatur~e, This can be monitc,red t o make certain that
is not significantly increased
the fetal t e mlerature
~
. . . .-- Electrornagnet~ctlelas (EM Fs)
and birth (defects
All6!ged to catJse abortic,, ,,, , , ,,,
Progestational dlrugs
Allc?gedto cause numerous types c,f non-gen
.- ital birth clefects,
including limb reduction defects, heart maltormatlons and many
er malforn

-

ROLE OF THE PHYSICIAN IN COUNSELING FAMILIES
The clinician must be cognizant of the fact that many patients believe that most
congenital malformations are caused by a drug or medication taken during
pregnancy. Counseling patients about reproductive risks requires a significant
degree of both knowledge and skill. Physicians must also realize that
erroneous counseling by inexperienced health professionals may be a stimulus
to non-meritorious l i t i g a t i ~ n . ~ ~
Unfortunately, some individuals have assumed that if a drug or chemical
causes birth defects in an animal model or in vitro system at a high dose, then
it has the potential for producing birth defects at any dose.48,49
This may be
reinforced by the fact that many teratology studies reported in the literature
using several doses do not determine the no-effect dose.
Ignoring the basic tenets of teratology appears to occur most commonly in the
evaluation of environmental toxic exposures where the exposure was very low or
unknown and the agent has been reported to be teratogenic at a very high dose or
a maternally toxic dose in animal models.48,"9 most instances, but of course not
all instances, the actual population exposure is revealed to be orders of magnitude
below the threshold dose and the doses that were used in animal studies or toxic
exposures in the population. This has occurred with 2,4,5-T, PCBs, Pb, Cd,
pesticides, herbicides, veterinary hormones and some industrial exposures.
Unfortunately, we do have examples where environmental disasters have
been responsible for birth defects or pregnancy loss in exposed populations
(methyl mercury in Japan, PCBs in the Orient, organic mercury in the Middle
East, lead poisoning in the 19th and early 20th centuries) and we do have many
examples of the introduction of teratogenic drugs (Table 6). Therefore, we can
never generalize as to whether a chemical or drug is safe or hazardous unless
we know the magnitude of the exposure.
Before their baby is born, parents may be concerned about the risks of
various environmental exposures. If the child is born with congenital
malformations they may question whether there was a causal relationship

with an environmental exposure:
1. H
as the environmental agent been proven to increase the risk of congenital
malformations in exposed human poptllatim? In other mds, is the agent a proven
human teratogen?
2. Should a zvomun of reproductive age or who is pregnant be concerned about increased
risks of reproductive efects from exposure to a particular environmental agent?

3. Ifa child is born zuith congenital malformationsand the mother was exposed during her
pregnancy to a particular environmental agent, was the agent responsible@ the child's
birth defcfs?
4. Should a physicinn report or publish a case ofa patient or cluster ofpatients who were
born with congenital rnalfmmations and whose mother was exposed to an
environmental agent?50
Scholarly evaluation

When a physician responds to a parent's inquiry ('What caused my child's
birth defect?'), the physician should respond in the same scholarly manner that
would be utilized in performing a differential diagnosis for any clinical
problem. Physicians have a protocol for evaluating complex clinical problems;
i.e. 'fever of unknown origin', 'failure to thrive', 'congestive heart failure', or
'respiratory distress'. If a mother of a malformed lnfant had some type of
exposure during pregnancy, such as a diagnostic radiological examination or
medication during pregnancy, the consulting physician should not support or
suggest the possibility of a causal relationship before performing a complete
evaluation. Likewise, if a pregnant woman who had not yet delivered had
some type of exposure during pregnancy, the consulting physician should not
support or suggest the possibility that the fetus is at increased risk before
performing a complete evaluation. As mentioned previously, only a small
percentage of birth defects are due to prescribed drugs, chemicals and physical
agents (Table 5).'.36fi Even when the drug is listed as a teratogen, it has to have
been administered during the sensitive period of development for that drug
and above the threshold dose for producing teratogenesis. Furthermore, the
malformations in the child should be the malformations that are included in
the teratogenic syndrome produced by that drug. It should be emphasized that
a recent analysis pointed out that there are no drugs with measurable
teratogenic potential in the list of the 200 most prescribed drugs in the US5'
After a complete examination of the child and a review of the genetic and
teratology medical literature, the clinician must decide on whether the child's
malformations are due to a genetic cause or an environmental toxin or agent.
The clinician may not be able to conclude, definitively or presumptively, the
etiology of the child's birth defects. This information must then be conveyed to
the patient in an objective and compassionate manner. A similar situation
exists if a pregnant women has been exposed to a drug, chemical or physical
agent, since the mother will want to know the risk of that exposure to her
unborn child. If one wishes to answer the generic question, 'Is a particular
environmental drug, chemical or physical agent a reproductive toxicant?' then
a formal approach is recommended that includes a 5-part evaluation as
described in Table l . I s

-,me typical analyses of the risks of reproductive effects for Bendectin, sex
diagnostic ultrasound, and electromagnetic fields demonstrate the
of an organized approach to determine whether an environmental
agent has been demonstrated to be a reproductive t o ~ i n . ~ '
There are resources that can assist the physician with the medical literature
and the clinical evaluation of the patient.5,6,",1"*4247
Clinical evaluation

There are many articles and books that can assist the physician with the clinical
evaluation, although physician training programs do not usually prepare
generalists to perform sophisticated genetic counseling or teratology
counseling."J6Besides the usual history and physical evaluation, the physician
has to obtain information about the nature, magnitude and timing of the
exposure. The physical examination should include descriptive and
quantitative information about the physical characteristics of the child. While
some growth measurements are routine, many measurements utilized by these
specialized counselors are not part of the usual physical examination, i.e.
palpebral fissure size, ear length, intercanthal distances, total height-to-trunk
ratio, and many others. Important physical variations in facial, hand and foot
structure as well as other anatomical structures may be suggestive of known
syndromes, either teratoiogic or genetic.
Evaluation of the reproductive risk of an environmental exposure that
occurred during pregnancy or the cause of a child's malformation in
which an exposure occurred during pregnancy

The vast majority of consultations involving pregnancy exposures conclude
that the exposure does not change the reproductive risks in that pregnancy. In
many instances, the information that is available is so vague that the counselor
cannot reach a definitive conclusion about the magnitude of the risk.
Information that is necessary for this evaluation is:

1. What was the nature of the exposure?
2. Is the exposure agent identifiable?If the agent is identifiable, has it been

definitively identified as a reproductive toxin with a recognized
constellation of malformations or other reproductive effects?

3. When did the exposure occur during embryonic and fetal development?

4. If the agent is known to produce reproductive toxic effects, was the
exposure above or below the threshold for these effects?
5. Were there other significant environmental exposures or medical problems
during the pregnancy?

6. Is this is a wanted pregnancy or is the family ambivalent about carrying
this baby to term?
7. What is the medical and reproductive history of this mother with regard
to prior pregnancies and the reproductive history of the family lineage?

Evaluation of the reproductive risk of an environmental exposure that
occurred during pregnancy

After obtaining all this information, the counselor is in a position to provide
the family with an estimate of the reproductive risks of the exposure. Here are
some examples of consultations that have been referred to our clinical
teratology service:
Patient 7
A 26-year-old pregnant woman was in an automobile accident in her 10th
week of pregnancy and sustained a severe concussion. Although she did not
convulse post-injury, the treating neurosurgeon prescribed 300 mg of
diphenylhydantoin during her first 24 hours in the hospital. Fortunately, she
recovered from the injury without any sequelae but her primary physician was
concerned that she had received an anticonvulsant associated with a
teratogenic syndrome. No other exposure to reproductive toxins occurred in
this pregnancy and the family history for congenital malformations was
negative, except for an uncle with neurofibromatosis. The primary physician
requested a consultation with regard to the teratogenic risk. While
diphenylhydantoin administered chronically throughout pregnancy has been
associated with a low incidence of characteristic facial dysmorphogenesis,
reduced mentation, clef palate and digital hypoplasia, there are no data to
indicate that one day of therapy would cause any of the features of this
syndrome. Furthermore, the lip and palate have completed their development
by the 10th week. This was a wanted pregnancy and the mother chose to
continue her pregnancy. She delivered a normal 3370-g boy at term.
Patient 2
A 25-year-old woman was seen in the emergency service of her local hospital
with nausea, vomiting and diarrhea. She had just returned from a cruise on
which a number of the passengers became ill on the last day of the trip with
similar symptoms. The emergency ward physician ordered a pregnancy test
followed by a flat plate of the abdomen because there was evidence of
peritoneal irritation. Both of these studies were negative. But 1 week later, she
missed her menstrual period and a week later her pregnancy test was positive.
Her obstetrician was concerned because she had been exposed to a
radiological procedure at a time when she was pregnant. The obstetrician
referred the patient for counseling after obtaining an ultrasound that indicated
that the embryo was approximately 7 days post-conception at the time of the
radiological examination. The patient advised the counselor that she was
ambivalent about the pregnancy because of the 'dangers' of the X-rays to her
embryo. The estimated exposure to the embryo was less than 500 mrad (0.005
Sv). This exposure is far below the exposure that is known to affect the
developing embryo. Just as important is the fact that the embryo was exposed
during the first 2 weeks post-conception, a time that is less likely to increase
the risk of teratogenesis, even if the exposure was much higher.26*52
After
evaluation of the family history and after she received counseling about the
risks of the X-ray, the prospective mother decided to continue the pregnancy.
She delivered a 3150-g normal baby.

tio on of whether a child born with congenital malformationswas
caused by an environmental exposure during pregnancy, has a genetic
etiology or whose cause cannot be determined
Patient 3
A mother of a 30-year-old man born in the Azores in 1960 with congenital
absence of the right leg below the knee had pursued compensation for her son
because she was certain that she must have received thalidomide during her
pregnancy.24The German manufacturer of thalidomide refused compensation
claiming that thalidomide had never been distributed in the Azores. The
mother fervently believed that thalidomide was responsible for her son's
malformations and I received a letter from her asking for my opinion. I
requested her son's medical records, X-rays and photographs of the
malformations. She sent me the X-ray studies of his hips and legs and his
complete evaluation performed at the local hospital in the Azores. He had
none of the other stigmata of thalidomide embryopathy (pre-axial limb
defects, phocomelia, facial hemangioma, ear malformations, deafness,
crocodile tears, ventricular septa1 defect, intestinal or gall bladder atresia,
kidney malformations). Most importantly, his limb malformations were not of
the thalidomide type. He had a unilateral congenital amputation, with no
digital remnants at the end of the limb. His pelvic girdle was completely
normal which would be unusual in a thalidomide malformed limb. Finally, his
limb defect involved only one leg; the other leg was completely normal. This
would be very unusual in a true thalidomide embryopathy. In this particular
case, the young man had a congenital amputation, probably due to vascular
disruption, etiology unknown. Known causes of vascular disruptive
malformations are cocaine, misoprostol and chorionic villous sampling. It is
difficult to determine whether any amount of appropriate counseling will put
closure on this problem for this mother.
Patient 4
A family claimed that the anti-nausea medication, B e n d e ~ t i n , 3taken
~ ~ ~ ,by
~ ~the
mother of a malformed boy, was responsible for her son's congenital limb
reduction defects. Bendectin was t,&en during the mother's pregnancy after
the period of limb organogenesis, but some limb malformations can be
produced by teratogens later in pregnancy. The malformation was
unaccompanied by any other dysmorphogenetic effects. The boy's
malformations were the classical split-hand, split-foot syndrome, which is
dominantly inherited. This malformation'has a significant portion of cases that
are due to a new mutation. Since neither parent manifested the malformation,
the conclusion had to be that a new mutation had occurred in the sex cells of
one of the parents. Therefore, the risk of this malformation occurring in the
offspring of this boy would be 50%. Obviously, Bendectin was not responsible
for this child's malformations. In spite of the obvious genetic etiology of the
malformed child's birth defects, a legal suit was filed. A jury decided for the
defendant - namely, that Bendectin was not responsible for the child's birth
defects.
It should be apparent that determining the reproductive risks of an exposure
during pregnancy or the etiology of a child's congenital malformations is not a

simple process. It involves a careful analysis of the medical and scientific
literature pertaining to the reproductive toxic effects of exogenous agents in
humans and animals, as well as an evaluation of the exposure and biological
plausibility of an increased risk or a causal connection between the exposure
and a child's congenital malformation. It also involves a careful physical
examination, a review of the scientific literature pertaining to genetic and
environmental causes of the malformations in question. Abridged counseling
based on superficial and incomplete analyses is a dis-service to the family.

CONCLUSIONS
There have been significant advances in embryology, teratology, reproductive
biology, genetics and epidemiology in the last
years that have provided
scientists and clinicians with a better perspective on the causes of congenital
malformations. We still cannot provide the families of children with
malformations a definitive diagnosis and etiology lor every malformed child.
However, there are numerous environmental drugs, chemicals and physical
agents that have been documented to produce congenital malformations and
reproductive effects. While this multitude of teratogenic agents (agents that
produce congenital malformations from exposures during pregnancy) account
for only a small proportion of malformations, it is important to remember that
all these environmentally produced birth defects are potentially preventable.
The most common known cause of congenital malformations is genetic, but
the largest group, unfortunately, is unknown. There are a number of important
clinical rules that are important for clinicians to utilize when determining the
cause of their patient's congenital malformations.

1. No teratogenic agent should be described qualitatively as a teratogen (an agent
that causes birth defects), since a teratogenic exposure includes not only the
agent, but also the dose and the time in pregnancy when the exposure occurs.
2. Even agents that have been demonstrated to result in malformations
cannot produce every type of malformation. Known teratogens may be
presumptively implicated by the spectrum of malformations they produce
(the syndrome that describes the clinical manifestations of the teratogenic
agent). It is easier to exclude an agent as a cause of birth defects than to
definitively conclude that it was responsible for birth defects, because of
the existence of genocopies of some teratogenic syndromes.

3. When evaluating the risk of exposures, the dose is a crucial component in
determining the risk. Teratogenic agents follow a toxicological
dose-response curve. This means that each teratogen has a threshold dose,
below which, there is no risk of teratogenesis, no matter when in
pregnancy the exposure occurred.

4. The evaluation of a child with congenital malformations cannot be
adequately performed unless it is approached with the same scholarship
and intensity as the evaluation of any other complicated medical problem.
5. Each physician must recognize the consequences of providing erroneous
reproductive risks to pregnant women exposed to drugs and chemicals

during pregnancy or alleging that a child's malformations are due to an
environmental agent without performing a complete and scholarly
evaluation.
6. Unfortunately, clinical teratology and clinical genetics are not emphasized
in medical school and residency education programs. But physicians have
a multitude of educational aids to assist them in their evaluations, which
include consultations with clinical teratologists and geneticists, the
medical literature and the OMIM website.
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